Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374075 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00374075 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 42 participants.
The verdict
NCT00374075, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.
Interventions
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374075
The ClinicalTrials.gov registry entry for NCT00374075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valproic Acid is the first listed.
NCT00374075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374075 about?
NCT00374075 is a clinical study titled "Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy". This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.
What is the current status of trial NCT00374075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2003-09. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00374075?
The interventions under investigation include: Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT00374075?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.